Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2018
At a glance
- Drugs Niraparib (Primary)
- Indications Lung cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms JASPER
- Sponsors TESARO
- 30 Sep 2018 Planned number of patients changed from 136 to 142.
- 30 Sep 2018 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 30 Sep 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2019.